AU Patent

AU2012321345B2 — Application of 5-HT6 receptor antagonists for the alleviation of cognitive deficits of down syndrome

Assigned to University of Utah Research Foundation Inc · Expires 2016-03-17 · 10y expired

What this patent protects

Methods for treating Down syndrome and improving cognitive function of a patient with an intellectual disability are disclosed. 5-hydroxytryptophan sub-receptor six (5-HT6) receptor antagonists are provided for improving the cognition of a Down syndrome patient.

USPTO Abstract

Methods for treating Down syndrome and improving cognitive function of a patient with an intellectual disability are disclosed. 5-hydroxytryptophan sub-receptor six (5-HT6) receptor antagonists are provided for improving the cognition of a Down syndrome patient.

Drugs covered by this patent

nirogacestat-hydrobromide (NIROGACESTAT HYDROBROMIDE)

Patent Metadata

Patent number: AU2012321345B2
Jurisdiction: AU
Classification: —
Expires: 2016-03-17
Drug substance claim: No
Drug product claim: No
Assignee: University of Utah Research Foundation Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.